Table of Contents
(Source: The Journal of Infectious Diseases)
Source: The Journal of Infectious Diseases - October 12, 2016 Category: Infectious Diseases Tags: Cover/Standing Material Source Type: research
Subscriptions Page
(Source: The Journal of Infectious Diseases)
Source: The Journal of Infectious Diseases - October 12, 2016 Category: Infectious Diseases Tags: Cover/Standing Material Source Type: research
Masthead
(Source: The Journal of Infectious Diseases)
Source: The Journal of Infectious Diseases - October 12, 2016 Category: Infectious Diseases Tags: Cover/Standing Material Source Type: research
Editorial Board
(Source: The Journal of Infectious Diseases)
Source: The Journal of Infectious Diseases - October 12, 2016 Category: Infectious Diseases Tags: Cover/Standing Material Source Type: research
Editorial Advisory Board
(Source: The Journal of Infectious Diseases)
Source: The Journal of Infectious Diseases - October 12, 2016 Category: Infectious Diseases Tags: Cover/Standing Material Source Type: research
Cover
(Source: The Journal of Infectious Diseases)
Source: The Journal of Infectious Diseases - October 12, 2016 Category: Infectious Diseases Tags: Cover/Standing Material Source Type: research
Passive Immunotherapy: Assessment of Convalescent Serum Against Ebola Virus Makona Infection in Nonhuman Primates
Conclusions. The findings suggest that convalescent sera alone is not sufficient for providing 100% protection against lethal ZEBOV infection when administered at the onset of viremia. (Source: The Journal of Infectious Diseases)
Source: The Journal of Infectious Diseases - October 4, 2016 Category: Infectious Diseases Authors: Mire, C. E., Geisbert, J. B., Agans, K. N., Thi, E. P., Lee, A. C. H., Fenton, K. A., Geisbert, T. W. Tags: MEDICAL COUNTERMEASURES Source Type: research
Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona
In conclusion, VSV-EBOV remains a potent and fast-acting prophylactic vaccine but demonstrates only limited efficacy in postexposure treatment. (Source: The Journal of Infectious Diseases)
Source: The Journal of Infectious Diseases - October 4, 2016 Category: Infectious Diseases Authors: Marzi, A., Hanley, P. W., Haddock, E., Martellaro, C., Kobinger, G., Feldmann, H. Tags: MEDICAL COUNTERMEASURES Source Type: research
Alisporivir Has Limited Antiviral Effects Against Ebola Virus Strains Makona and Mayinga
Antiviral therapeutics with existing clinical safety profiles would be highly desirable in an outbreak situation, such as the 2013–2016 emergence of Ebola virus (EBOV) in West Africa. Although, the World Health Organization declared the end of the outbreak early 2016, sporadic cases of EBOV infection have since been reported. Alisporivir is the most clinically advanced broad-spectrum antiviral that functions by targeting a host protein, cyclophilin A (CypA). A modest antiviral effect of alisporivir against contemporary (Makona) but not historical (Mayinga) EBOV strains was observed in tissue culture. However, this ef...
Source: The Journal of Infectious Diseases - October 4, 2016 Category: Infectious Diseases Authors: Chiramel, A. I., Banadyga, L., Dougherty, J. D., Falzarano, D., Martellaro, C., Brees, D., Taylor, R. T., Ebihara, H., Best, S. M. Tags: MEDICAL COUNTERMEASURES Source Type: research
An Inactivated Rabies Virus-Based Ebola Vaccine, FILORAB1, Adjuvanted With Glucopyranosyl Lipid A in Stable Emulsion Confers Complete Protection in Nonhuman Primate Challenge Models
The 2013–2016 West African Ebola virus (EBOV) disease outbreak was the largest filovirus outbreak to date. Over 28 000 suspected, probable, or confirmed cases have been reported, with a 53% case-fatality rate. The magnitude and international impact of this EBOV outbreak has highlighted the urgent need for a safe and efficient EBOV vaccine. To this end, we demonstrate the immunogenicity and protective efficacy of FILORAB1, a recombinant, bivalent, inactivated rabies virus–based EBOV vaccine, in rhesus and cynomolgus monkeys. Our results demonstrate that the use of the synthetic Toll-like receptor 4 agonist gluco...
Source: The Journal of Infectious Diseases - October 4, 2016 Category: Infectious Diseases Authors: Johnson, R. F., Kurup, D., Hagen, K. R., Fisher, C., Keshwara, R., Papaneri, A., Perry, D. L., Cooper, K., Jahrling, P. B., Wang, J. T., ter Meulen, J., Wirblich, C., Schnell, M. J. Tags: MEDICAL COUNTERMEASURES Source Type: research
Preliminary Evaluation of the Effect of Investigational Ebola Virus Disease Treatments on Viral Genome Sequences
Conclusions. This small subset of patients and clinical specimens suggests that evolution of resistance is not a direct consequence of antiviral treatment. As EVD antiviral treatments are introduced into wider use, it is essential that continuous viral full-genome surveillance is performed, to monitor for the emergence of escape mutations. (Source: The Journal of Infectious Diseases)
Source: The Journal of Infectious Diseases - October 4, 2016 Category: Infectious Diseases Authors: Whitmer, S. L. M., Albarino, C., Shepard, S. S., Dudas, G., Sheth, M., Brown, S. C., Cannon, D., Erickson, B. R., Gibbons, A., Schuh, A., Sealy, T., Ervin, E., Frace, M., Uyeki, T. M., Nichol, S. T., Ströher, U. Tags: MEDICAL COUNTERMEASURES Source Type: research
An Adenovirus Vaccine Expressing Ebola Virus Variant Makona Glycoprotein Is Efficacious in Guinea Pigs and Nonhuman Primates
A licensed vaccine against Ebola virus (EBOV) remains unavailable, despite >11 000 deaths from the 2014–2016 outbreak of EBOV disease in West Africa. Past studies have shown that recombinant vaccine viruses expressing EBOV glycoprotein (GP) are able to protect nonhuman primates (NHPs) from a lethal EBOV challenge. However, these vaccines express the viral GP–based EBOV variants found in Central Africa, which has 97.3% amino acid homology to the Makona variant found in West Africa. Our previous study showed that a recombinant adenovirus serotype 5 (Ad5)–vectored vaccine expressing the Makona EBOV GP (Ma...
Source: The Journal of Infectious Diseases - October 4, 2016 Category: Infectious Diseases Authors: Wu, S., Kroeker, A., Wong, G., He, S., Hou, L., Audet, J., Wei, H., Zhang, Z., Fernando, L., Soule, G., Tran, K., Bi, S., Zhu, T., Yu, X., Chen, W., Qiu, X. Tags: MEDICAL COUNTERMEASURES Source Type: research
FAM134B, the Selective Autophagy Receptor for Endoplasmic Reticulum Turnover, Inhibits Replication of Ebola Virus Strains Makona and Mayinga
Selective autophagy of the endoplasmic reticulum (termed ER-phagy) is controlled by members of the FAM134 reticulon protein family. Here we used mouse embryonic fibroblasts from mice deficient in FAM134B to examine the role of the ER in replication of historic (Mayinga) or contemporary (Makona GCO7) strains of Ebola virus (EBOV). Loss of FAM134B resulted in 1–2 log10 higher production of infectious EBOV, which was associated with increased production of viral proteins GP and VP40 and greater accumulation of nucleocaspid lattices. In addition, only 10% of wild-type cells contained detectable nucleoprotein, whereas kno...
Source: The Journal of Infectious Diseases - October 4, 2016 Category: Infectious Diseases Authors: Chiramel, A. I., Dougherty, J. D., Nair, V., Robertson, S. J., Best, S. M. Tags: PATHOGENESIS Source Type: research
Ebola Virus Replication and Disease Without Immunopathology in Mice Expressing Transgenes to Support Human Myeloid and Lymphoid Cell Engraftment
The study of Ebola virus (EBOV) pathogenesis in vivo has been limited to nonhuman primate models or use of an adapted virus to cause disease in rodent models. Herein we describe wild-type EBOV (Makona variant) infection of mice engrafted with human hematopoietic CD34+ stem cells (Hu-NSG™-SGM3 mice; hereafter referred to as SGM3 HuMice). SGM3 HuMice support increased development of myeloid immune cells, which are primary EBOV targets. In SGM3 HuMice, EBOV replicated to high levels, and disease was observed following either intraperitoneal or intramuscular inoculation. Despite the high levels of viral antigen and infla...
Source: The Journal of Infectious Diseases - October 4, 2016 Category: Infectious Diseases Authors: Spengler, J. R., Lavender, K. J., Martellaro, C., Carmody, A., Kurth, A., Keck, J. G., Saturday, G., Scott, D. P., Nichol, S. T., Hasenkrug, K. J., Spiropoulou, C. F., Feldmann, H., Prescott, J. Tags: PATHOGENESIS Source Type: research
Broad and Temperature Independent Replication Potential of Filoviruses on Cells Derived From Old and New World Bat Species
In this study, we determined the replication potential of all filovirus species: Marburg marburgvirus, Taï Forest ebolavirus, Reston ebolavirus, Sudan ebolavirus, Zaire ebolavirus, and Bundibugyo ebolavirus. Filovirus replication was supported by all cell lines derived from 6 Old and New World bat species: the hammer-headed fruit bat, Buettikofer's epauletted fruit bat, the Egyptian fruit bat, the Jamaican fruit bat, the Mexican free-tailed bat and the big brown bat. In addition, we showed that Marburg virus Angola and Ebola virus Makona-WPGC07 efficiently replicated at 37°C, 37°–41°C, or 41°C...
Source: The Journal of Infectious Diseases - October 4, 2016 Category: Infectious Diseases Authors: Miller, M. R., McMinn, R. J., Misra, V., Schountz, T., Müller, M. A., Kurth, A., Munster, V. J. Tags: PATHOGENESIS Source Type: research
